Quidel Corporation is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel's comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel's mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of families, communities and the world.

Company profile
Ticker
QDEL
Exchange
Website
CEO
Douglas Bryant
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Diagnostic Hybrids, Inc. • Quidel Cardiovascular Inc. • Quidel Ireland Limited • Quidel China Ltd. ...
IRS number
942573850
QDEL stock data
News
UPDATE: Quidel Q2 Adj. EPS $2.12 May Not Compare To $3.07 Estimate
4 Aug 22
Quidel Q2 Sales $613.40M Beat $565.80M Estimate
4 Aug 22
Earnings Scheduled For August 4, 2022
4 Aug 22
Overview Of Value Stocks In The Healthcare Sector
25 Jul 22
LabCorp (LH) To Report Q2 Earnings: What's In The Cards?
20 Jul 22
Press releases
QuidelOrtho Reports Second Quarter 2022 Financial Results
4 Aug 22
ORTHO RANKS NO. 1 IN CUSTOMER SATISFACTION FOR 5 YEARS IN A ROW
26 Jul 22
QuidelOrtho to Report Second Quarter 2022 Financial Results on August 4, 2022
18 Jul 22
Quidel Corporation and the American Heart Association join forces to Advance Education and Awareness of Heart Disease in San Diego County
21 Jun 22
QUIDEL CORP.—DEVELOPER OF ONLY FDA-CLEARED FIA RAPID POINT-OF-CARE DIAGNOSTIC LYME DISEASE TEST—TO PARTNER WITH RENOWNED GLOBAL LYME ALLIANCE TO DRAMATICALLY HEIGHTEN LYME DISEASE AWARENESS
9 Jun 22
Analyst ratings and price targets
Calendar
4 May 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 May 22 | Bryant Douglas C | Common Stock | Sale back to company | Dispose D | No | No | 0 | 505,926 | 0 | 0 |
27 May 22 | Bryant Douglas C | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 794 | 0 | 0 |
27 May 22 | Bryant Douglas C | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 2,646 | 0 | 0 |
27 May 22 | Bryant Douglas C | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 24,187 | 0 | 0 |
27 May 22 | Bryant Douglas C | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 27,043 | 0 | 0 |
27 May 22 | Bryant Douglas C | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 3,347 | 0 | 0 |
27 May 22 | Bryant Douglas C | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 2,921 | 0 | 0 |
27 May 22 | Bryant Douglas C | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 7,590 | 0 | 0 |
27 May 22 | Bryant Douglas C | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 2,192 | 0 | 0 |
27 May 22 | Bryant Douglas C | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 7,309 | 0 | 0 |
Institutional ownership, Q1 2022
61.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 352 |
Opened positions | 65 |
Closed positions | 74 |
Increased positions | 141 |
Reduced positions | 96 |
13F shares | Current |
---|---|
Total value | 4.57B |
Total shares | 40.89M |
Total puts | 678.1K |
Total calls | 569.6K |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
TROW T. Rowe Price | 6.17M | $693.57M |
Vanguard | 3.43M | $386.26M |
BLK Blackrock | 3.23M | $362.82M |
Brown Capital Management | 2.34M | $263.69M |
Alger Associates | 2.22M | $0 |
Senvest Management | 2.01M | $226.54M |
Larry N Feinberg | 1.81M | $325.12M |
Fred Alger Management | 1.71M | $192.2M |
ArrowMark Colorado | 1.5M | $168.15M |
STT State Street | 1.11M | $124.46M |
Financial report summary
?Competition
Abbott Laboratories • Thermo Fisher Scientific • Danaher • Meridian Bioscience • Luminex • TearLab • MyMD Pharmaceuticals • Great Basin Scientific • Talis Biomedical • Lucira HealthRisks
- The COVID-19 global pandemic could adversely affect our business operations, strategy, financial performance and results of operations, the extent of which is uncertain and difficult to predict.
- The industry and market segment in which we operate are highly competitive, and intense competition with other providers of diagnostic products or services may reduce our sales and margins.
- Our operating results are heavily dependent on sales of our COVID-19 and influenza diagnostic tests and if sales or revenues of our COVID-19 or influenza tests decline for any reason, our operating results would be materially and adversely affected.
- We rely on a limited number of key distributors that account for a significant portion of our total revenue. The loss of any key distributor or an unsuccessful effort by us to directly distribute our products could lead to reduced sales.
- Our results of operations and financial condition may be adversely affected by the financial soundness of our customers and suppliers.
- We may not achieve market acceptance of our products among physicians, healthcare providers or other customers, and this would have a negative effect on future sales.
- Our total revenue could be affected by third-party reimbursement policies and potential cost constraints.
- Unexpected increases in, or inability to meet, demand for our products and services could require us to spend considerable resources to meet the demand or harm our reputation and customer relationships if we are unable to meet demand.
- Interruptions in the supply of raw materials, components, equipment and other products and services could adversely affect our operations and financial results.
- Failures in our IT and storage systems, including as a result of cyber-security breaches, could significantly disrupt our business or force us to expend excessive costs.
- Interruptions to our third-party IT service providers and/or the inability of our digital solutions to interoperate with certain operating systems could impair the delivery of our cloud-based solutions and negatively impact our business.
- We face risks relating to our international sales, including inherent economic, political and regulatory risks, that could impact our financial performance, cause interruptions in our current business operations and impede our growth strategy.
- Continuing worldwide political and social uncertainty, including tariffs, trade wars or social tensions, may adversely affect our business and prospects, both domestically and internationally.
- Natural disasters, public health crises, political crises and other catastrophic events or other events outside of our control may disrupt our facilities or the facilities of third parties on which we depend and adversely affect our results of operations.
- Risks Related to Our Pending Business Combination
- Completion of the Combinations is subject to certain conditions, some of which are outside of the parties’ control, and if these conditions are not satisfied or waived, the Combinations will not be completed.
- Failure to complete the Combinations could negatively impact our stock price and future business and financial results.
- The BCA contains provisions that restrict our ability to pursue alternatives to the Combinations and, in specified circumstances, would require us to pay Ortho a termination fee.
- We will incur significant transaction and merger-related costs in connection with the Combinations.
- We may have difficulty attracting, motivating and retaining executives and other key employees due to uncertainty associated with the Combinations.
- Our business relationships may be subject to disruption due to uncertainty associated with the Combinations.
- Completion of the Combinations may trigger change-in-control or other provisions in certain agreements that we are party to.
- Intellectual Property Risks
- To remain competitive, we must continue to develop and obtain proprietary technology rights; otherwise, we may lose market share or need to reduce prices as a result of competitors selling lower priced or technologically superior products or services that compete with our products.
- Intellectual property risks and third-party claims of infringement, misappropriation of proprietary rights or other claims against us could adversely affect our ability to market our products, require us to redesign our products or attempt to seek licenses from third parties, and materially adversely affect our operating results. In addition, the defense of such claims could result in significant costs and divert the attention of our management and other key employees.
- Our COVID-19 products were approved by the FDA through an EUA and the loss of such authorization could have a material adverse impact on our business, results of operations, financial position and cash flows.
- Our business and products are highly regulated by various governmental agencies. Our results of operations would be negatively affected by failures or delays in the receipt of regulatory approvals, clearances or authorizations, the loss of previously received approvals or other changes to existing laws and regulations that adversely impact our ability to manufacture and market our products.
- Our contracts with government entities involve future funding, compliance, and possible sanctions risks.
- If one or more of our products is claimed to be defective, we could be subject to claims of liability and harm to our reputation that could adversely affect our business.
- We use hazardous materials in our business that may result in substantial claims against us relating to handling, storage or disposal.
- Complying with various US federal, state and foreign privacy and data security laws and privacy requirements from our customers could cause us to incur substantial costs or require us to change our business practices in a manner adverse to our business.
- Changes in tax law relating to multinational corporations could adversely affect our tax position.
- Risks Related to Our Acquisitions
- If we are not able to manage our growth strategy or if we experience difficulties identifying or integrating companies or technologies we may acquire, our operating results may be adversely affected.
- Transitioning the BNP Business to Beckman presents certain risks to our business and operations.
- We may need to raise additional funds to finance our future capital or operating needs, which could have adverse consequences on our operations and the interests of our stockholders.
- Our debt, deferred and contingent payment obligations could materially adversely affect our financial condition and results of operations.
- Our business could be negatively affected by the loss of or the inability to hire key personnel.
- We are subject to, and may in the future become subject to, claims and litigation that could result in significant expenses and could ultimately result in an unfavorable outcome for us.
- We are exposed to business risk which, if not covered by insurance, could have an adverse effect on our results of operations.
- Changes in our tax rates or exposure to additional income tax liabilities or assessments could affect our profitability.
- Some provisions of our charter documents and Delaware law may make takeover attempts difficult, which could depress the price of our common stock and inhibit our stockholders’ ability to receive a premium price for their shares.
- Expectations of our performance related to ESG matters may impose additional costs on us and expose us to new risks.
Management Discussion
- Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31. Fiscal year 2021 was 52 weeks and fiscal year 2020 was 53 weeks.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
BCA, billion, Canadian, codified, compensatory, concentrated, consummation, Coronado, forma, fully, geopolitical, guidance, Holdco, human, immaterial, Incentive, Laguna, Letter, list, merger, mission, Nasdaq, Natriuretic, nominee, Orca, Ortho, paper, pay, plc, preliminary, pro, proposed, Retention, Retirement, scheme, small, surviving, Topco, Topic, UK, undertaken
Removed:
absorb, antitrust, arising, assumed, back, beneficiary, billed, collected, computer, contractually, conversion, convertible, County, coupon, court, created, decide, decline, denominator, designed, distancing, distribution, entity, exceeded, exclusivity, expanded, facilitating, Family, favorable, finance, granting, half, inception, incur, infrastructure, Institute, instrument, issue, key, lawsuit, leaseback, licensing, limited, mask, matured, maturity, McKellar, meeting, milestone, narrow, Naturietic, NIH, obligation, offsetting, partner, partnership, power, preventative, proceed, productivity, protect, referred, reimbursed, relating, roll, safeguard, sale, Senior, show, social, sort, structured, successfully, Superior, trade, travel, trial, unbilled, unconsolidated, unemployment, unenforceable, variable, VIE, wearing
Financial reports
Current reports
8-K
Submission of Matters to a Vote of Security Holders
16 May 22
8-K
Other Events
6 May 22
8-K
Quidel Reports First Quarter 2022 Financial Results
4 May 22
8-K
Quidel Announces Preliminary Revenue for First Quarter 2022
7 Apr 22
8-K
Quidel Reports Fourth Quarter and Full Year 2021 Financial Results
17 Feb 22
8-K
Other Events
14 Feb 22
8-K
Departure of Directors or Certain Officers
4 Feb 22
8-K
Departure of Directors or Certain Officers
27 Jan 22
8-K
QUIDEL TO PRESENT VIRTUALLY AT 40th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
6 Jan 22
8-K
Quidel Corporation Signs Definitive Agreement to Acquire Ortho Clinical Diagnostics
23 Dec 21
Registration and prospectus
15-12G
Securities registration termination
6 Jun 22
25-NSE
Exchange delisting
27 May 22
425
Business combination disclosure
6 May 22
425
Business combination disclosure
4 May 22
425
Business combination disclosure
4 May 22
425
Business combination disclosure
17 Feb 22
425
Business combination disclosure
17 Feb 22
425
Business combination disclosure
14 Feb 22
425
Business combination disclosure
4 Feb 22
425
Business combination disclosure
18 Jan 22
Other
SD
Conflict minerals disclosure
26 May 22
SD
Conflict minerals disclosure
1 Jun 21
SD
Conflict minerals disclosure
29 May 20
SD
Conflict minerals disclosure
31 May 19
SD
Conflict minerals disclosure
30 May 18
SD
Conflict minerals disclosure
30 May 17
SD
Conflict minerals disclosure
30 May 16
SD
Conflict minerals disclosure
31 May 15
UPLOAD
Letter from SEC
21 Oct 14
CORRESP
Correspondence with SEC
22 Sep 14
Ownership
4
QUIDEL / Tamara A. Ranalli ownership change
1 Jun 22
4
QUIDEL / Matthew Strobeck ownership change
1 Jun 22
4
QUIDEL / ANN D RHOADS ownership change
1 Jun 22
4
QUIDEL / KENNETH J WIDDER ownership change
1 Jun 22
4
QUIDEL / MARY LAKE PH D POLAN ownership change
1 Jun 22
4
QUIDEL / Michelle A. Hodges ownership change
1 Jun 22
4
QUIDEL / Robert Joseph Bujarski ownership change
1 Jun 22
4
QUIDEL / Edward L. Michael ownership change
1 Jun 22
4
QUIDEL / Werner Kroll ownership change
1 Jun 22
4
QUIDEL / Joseph D Jr. Wilkins ownership change
1 Jun 22
Patents
Utility
System and Methods for Remote Assessment of a Sample Assay for Disease Diagnostics
3 Mar 22
A method for performing a lateral flow assay is provided.
Utility
Immunoassay controls and the use thereof
1 Feb 22
The present invention relates to compositions and methods use in designing immunoassay controls.
Utility
Immunoassay Test Device with Two Fluid Flow Paths for Detection and Differentiation of Two or More Analytes
23 Dec 21
A device for determining presence or absence of infection due to an infectious agent is described.
Utility
System and Apparatus for Point-of-care Diagnostics
16 Dec 21
A system comprised of an apparatus and a test device is described.
Utility
System and Methods for Remote Assessment of a Sample Assay for Disease Diagnostics
2 Dec 21
A circuit in an image-capturing device is provided.
Transcripts
2022 Q2
Earnings call transcript
5 Aug 22
2022 Q1
Earnings call transcript
5 May 22
2021 Q4
Earnings call transcript
18 Feb 22
2021 Q3
Earnings call transcript
5 Nov 21
2021 Q2
Earnings call transcript
6 Aug 21
2021 Q1
Earnings call transcript
7 May 21
2020 Q4
Earnings call transcript
19 Feb 21
2020 Q3
Earnings call transcript
29 Oct 20
2020 Q2
Earnings call transcript
31 Jul 20
2020 Q1
Earnings call transcript
6 May 20
Reddit threads
Calculating the ev/fcf of two combining companies?
6 Jul 22
r/Stocks Daily Discussion Wednesday - Jul 06, 2022
6 Jul 22
How will this acquisition work? Help me understand please
3 Jul 22
What stocks down 70% or more do you think will rebound from the current bubble that is popping?
18 Jun 22
Daily Discussion - Wednesday June 01 2022
1 Jun 22
What’s your favourite stock right now?
31 May 22
r/Stocks Daily Discussion & Technicals Tuesday - May 31, 2022
31 May 22
Daily Discussion - Tuesday May 31 2022
31 May 22
[Weekly Megathread] Markets and Value Stock Ideas, Week of May 30, 2022
30 May 22
Never invest more than 15% of Your Savings in Anything!
24 May 22